OLMA vs. XNCR, SYRE, ETNB, OCUL, RCUS, AUPH, SPRY, ADPT, GYRE, and MRVI
Should you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Xencor (XNCR), Spyre Therapeutics (SYRE), 89bio (ETNB), Ocular Therapeutix (OCUL), Arcus Biosciences (RCUS), Aurinia Pharmaceuticals (AUPH), ARS Pharmaceuticals (SPRY), Adaptive Biotechnologies (ADPT), Gyre Therapeutics (GYRE), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.
Olema Pharmaceuticals vs.
Xencor (NASDAQ:XNCR) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, community ranking, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.
Olema Pharmaceuticals has lower revenue, but higher earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Xencor currently has a consensus target price of $34.88, indicating a potential upside of 121.57%. Olema Pharmaceuticals has a consensus target price of $28.75, indicating a potential upside of 476.15%. Given Olema Pharmaceuticals' higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Xencor.
Olema Pharmaceuticals has a net margin of 0.00% compared to Xencor's net margin of -232.77%. Xencor's return on equity of -30.92% beat Olema Pharmaceuticals' return on equity.
Xencor received 475 more outperform votes than Olema Pharmaceuticals when rated by MarketBeat users. Likewise, 73.44% of users gave Xencor an outperform vote while only 67.39% of users gave Olema Pharmaceuticals an outperform vote.
In the previous week, Olema Pharmaceuticals had 5 more articles in the media than Xencor. MarketBeat recorded 6 mentions for Olema Pharmaceuticals and 1 mentions for Xencor. Olema Pharmaceuticals' average media sentiment score of 0.71 beat Xencor's score of 0.00 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.
Xencor has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500.
91.8% of Olema Pharmaceuticals shares are held by institutional investors. 5.2% of Xencor shares are held by insiders. Comparatively, 19.4% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Olema Pharmaceuticals beats Xencor on 10 of the 18 factors compared between the two stocks.
Get Olema Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olema Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:OLMA) was last updated on 2/22/2025 by MarketBeat.com Staff
Free OLMA Stock Alerts